Ly(上标 +)-AML和Ly(上标 -)-AML在FAB和WHO分型中的分布及治疗反应

Aim To investigate distribution and therapeutic response of lymphoid surface antigen-positive acute myeloid leukemia (Ly(superscript +)-AML) and lymphoid surface antigen-negative acute myeloid leukemia (Ly(superscript -)-AML) in FAB and WHO classification. Methods: Bone marrow aspirates from 117 adult patients with newly diagnosed de novo acute myeloid leukemia (AML) were analyzed. The diagnosis was made through standard morphologic examination and cytochemical analysis by the French-American-British (FAB) Cooperative Study Group and through immunophenotyping with a panel of monoclonal antibodies against myeloid-and lymphoid-associated antigens by European Group of International Leukemia (EGIL) scoring system. All chromosome karyotypes were analyzed through G-Band technique. 115 of those cases were typed by a new World Health Organization (WHO) classification of haematological malignancies. After all patients were treated with a standard remission induction regimen for 1 course, their Bone marrow aspirates were Wrigth-Gimsa-stained and the therapeutic effect was analyzed. Results: According to FAB criteria, 117 cases were classified as acute myeloid leukemia. After immunologic phenotyping, 89 cases (76.1%) were classified as Ly(superscript +)-AML. 28 cases (23.9%) were classified as Ly(superscript +)-AML. Of WHO typing, 23.1% of Ly(superscript -)-AML cases was AML with recurrent genetic abnormalities. The patients with Ly(superscript +)-AML had a significantly higher incidence of these karyotypic abnormalities compared with Ly(superscript -)-AML (50.5% v 23.1%, P=0.013). After induction therapy, Complete remission (CR) rate of Ly(superscript +)-AML and Ly(superscript -)-AML was 69.7% and 34.6% respectively (P=0.001). Conclusion: Leukemic cell immunotyping can reflect the cell origin and differentiation stage objectively. After induction therapy, CR rate of Ly(superscript -)-AML was higher than that of Ly(superscript +)-AML (P=0.001).